1.
Garau J. Why do we need to eradicate pathogens in res- piratory tract infections? Int J Infect Dis 2003;Suppl 1:S005-10.
2.
File T.M. Jr., Jacobs M.R., Poole M.D., Wynne B., 546–551, 556, 557 and 592 Clinical Study Groups. Outcome of treatment of respiratory tract infections due to Streptococcus pneumoniae, including drug-resistant strains, with pharmacokinetically enhanced amoxycil- lin/clavulanate. Int J Antimicrob Agents 2002;20:235-47.
3.
Todd P.A., Benfield P. Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1990;39:264-307.
4.
Data on file Lek D.D. 2003.
5.
Vree T.B., Dammers E., Exler P. Identical pattern of highly variable absorption of clavulanic acid from four different oral formulations of co-amoxiclav in healthy subjects. J Antimicrob Chemother 2003;51:373-78.